α(t) | MEN in [26] | MEN in [27] | ME36 | ME64 |
0.5 | 8.82×10−4 | 1.99×10−4 | 1.41×10−5 | 4.18×10−6 |
0.8 | 8.50×10−4 | 1.87×10−4 | 7.16×10−6 | 4.61×10−6 |
0.01 | 1.43×10−5 | 4.09×10−6 | ||
0.99 | 2.95×10−5 | 6.03×10−6 |
Clopidogrel is a purinergic receptor P2Y12 (P2RY12)-blocking pro-drug used to inhibit platelet aggregation in patients at risk for major adverse cardiac events (MACE), such as coronary artery disease and stroke. Despite clopidogrel therapy, some patients may still present with recurrent cardiovascular events. One possible cause of recurrence are variants in the cytochrome P450 2C19 (CYP2C19) gene. CYP2C19 is responsible for the metabolism of many drugs including clopidogrel. Recent studies have associated pharmacogenetics testing of CYP2C19 variants to guide clopidogrel therapy with a decreased risk of certain recurrent MACEs. Through a different mechanism, diabetes mellitus (DM) and obesity are also associated with clopidogrel treatment failure. We describe the case of a 64-year-old Caucasian woman with a history of acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI), and DM/obesity, who presented to University of Texas Medical Branch (UTMB) in 2019 with a transient ischemic attack (TIA) while on clopidogrel/aspirin dual anti-platelet therapy. After CYP2C19 genetic testing revealed that she was an intermediate metabolizer with a heterozygous *2 genotype, ticagrelor replaced the clopidogrel treatment regimen. No future MACEs were documented in the two-year patient follow-up. Thus, ACS patients with DM/obesity who have undergone PCI and are intermediate CYP2C19 metabolizers may yield better treatment outcomes if prescribed ticagrelor instead of clopidogrel. Whether this improvement was due to genotype-guided therapy or the differing interactions of clopidogrel/ticagrelor in DM/obese patients is unknown based on available data. Regardless, CYP2C19 genotype-guided treatment of ACS/PCI patients, with consideration of DM/obesity status, may provide effective individualized therapy compared to standard treatment. The inclusion of DM/obesity in this study is clinically relevant because DM/obesity has become a major health issue in the United States and worldwide.
Citation: Rahel Tekeste, Gregorio Garza, Song Han, Jianli Dong. Ticagrelor is more effective than clopidogrel in carrier of nonfunctional CYP2C19 allele who has diabetes and acute coronary syndrome - case report and literature review[J]. AIMS Molecular Science, 2022, 9(2): 66-78. doi: 10.3934/molsci.2022004
[1] | Yingchao Zhang, Yuntao Jia, Yingzhen Lin . An $ {\varepsilon} $-approximate solution of BVPs based on improved multiscale orthonormal basis. AIMS Mathematics, 2024, 9(3): 5810-5826. doi: 10.3934/math.2024282 |
[2] | Liangcai Mei, Boying Wu, Yingzhen Lin . Shifted-Legendre orthonormal method for high-dimensional heat conduction equations. AIMS Mathematics, 2022, 7(5): 9463-9478. doi: 10.3934/math.2022525 |
[3] | Hui Zhu, Liangcai Mei, Yingzhen Lin . A new algorithm based on compressed Legendre polynomials for solving boundary value problems. AIMS Mathematics, 2022, 7(3): 3277-3289. doi: 10.3934/math.2022182 |
[4] | Xiaoyong Xu, Fengying Zhou . Orthonormal Euler wavelets method for time-fractional Cattaneo equation with Caputo-Fabrizio derivative. AIMS Mathematics, 2023, 8(2): 2736-2762. doi: 10.3934/math.2023144 |
[5] | Obaid Algahtani, M. A. Abdelkawy, António M. Lopes . A pseudo-spectral scheme for variable order fractional stochastic Volterra integro-differential equations. AIMS Mathematics, 2022, 7(8): 15453-15470. doi: 10.3934/math.2022846 |
[6] | Zihan Yue, Wei Jiang, Boying Wu, Biao Zhang . A meshless method based on the Laplace transform for multi-term time-space fractional diffusion equation. AIMS Mathematics, 2024, 9(3): 7040-7062. doi: 10.3934/math.2024343 |
[7] | A.S. Hendy, R.H. De Staelen, A.A. Aldraiweesh, M.A. Zaky . High order approximation scheme for a fractional order coupled system describing the dynamics of rotating two-component Bose-Einstein condensates. AIMS Mathematics, 2023, 8(10): 22766-22788. doi: 10.3934/math.20231160 |
[8] | Yones Esmaeelzade Aghdam, Hamid Mesgarani, Zeinab Asadi, Van Thinh Nguyen . Investigation and analysis of the numerical approach to solve the multi-term time-fractional advection-diffusion model. AIMS Mathematics, 2023, 8(12): 29474-29489. doi: 10.3934/math.20231509 |
[9] | Bin Fan . Efficient numerical method for multi-term time-fractional diffusion equations with Caputo-Fabrizio derivatives. AIMS Mathematics, 2024, 9(3): 7293-7320. doi: 10.3934/math.2024354 |
[10] | Dina Abdelhamid, Wedad Albalawi, Kottakkaran Sooppy Nisar, A. Abdel-Aty, Suliman Alsaeed, M. Abdelhakem . Mixed Chebyshev and Legendre polynomials differentiation matrices for solving initial-boundary value problems. AIMS Mathematics, 2023, 8(10): 24609-24631. doi: 10.3934/math.20231255 |
Clopidogrel is a purinergic receptor P2Y12 (P2RY12)-blocking pro-drug used to inhibit platelet aggregation in patients at risk for major adverse cardiac events (MACE), such as coronary artery disease and stroke. Despite clopidogrel therapy, some patients may still present with recurrent cardiovascular events. One possible cause of recurrence are variants in the cytochrome P450 2C19 (CYP2C19) gene. CYP2C19 is responsible for the metabolism of many drugs including clopidogrel. Recent studies have associated pharmacogenetics testing of CYP2C19 variants to guide clopidogrel therapy with a decreased risk of certain recurrent MACEs. Through a different mechanism, diabetes mellitus (DM) and obesity are also associated with clopidogrel treatment failure. We describe the case of a 64-year-old Caucasian woman with a history of acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI), and DM/obesity, who presented to University of Texas Medical Branch (UTMB) in 2019 with a transient ischemic attack (TIA) while on clopidogrel/aspirin dual anti-platelet therapy. After CYP2C19 genetic testing revealed that she was an intermediate metabolizer with a heterozygous *2 genotype, ticagrelor replaced the clopidogrel treatment regimen. No future MACEs were documented in the two-year patient follow-up. Thus, ACS patients with DM/obesity who have undergone PCI and are intermediate CYP2C19 metabolizers may yield better treatment outcomes if prescribed ticagrelor instead of clopidogrel. Whether this improvement was due to genotype-guided therapy or the differing interactions of clopidogrel/ticagrelor in DM/obese patients is unknown based on available data. Regardless, CYP2C19 genotype-guided treatment of ACS/PCI patients, with consideration of DM/obesity status, may provide effective individualized therapy compared to standard treatment. The inclusion of DM/obesity in this study is clinically relevant because DM/obesity has become a major health issue in the United States and worldwide.
In the past few decades, more and more diffusion processes have been shown to not satisfy Fickian laws, such as signal transduction in biological cells, foraging behavior of animals, viscoelastic and viscoplastic flow, and solute migration in groundwater. However, fractional partial differential equations (FPDEs) play a very important role in describing anomalous diffusion Ref. [1,2,3], so in recent years, FPDEs have attracted extensive attention. In this paper, we study one type of time-fractional diffusion equation (TFDE), which can be obtained from the standard diffusion equation by replacing the first-order time derivative with a fractional derivative of order α, 0<α<1.
{Dαtu(x,t)=uxx(x,t)+f(x,t),(x,t)∈(0,b)×(0,T],u(x,0)=u0(x),x∈[0,b],u(0,t)=0),u(b,t)=0,t∈[0,T]. | (1.1) |
Where u0(x) is a smooth function and Dαtu(x,t) is the Caputo fractional derivative defined by Definition 2.1.
The exact solutions of most fractional differential equations are difficult to obtain analytically, and even if they can be obtained, most of them contain special functions that are difficult to calculate. In recent years, many numerical methods have been proposed. For example, Ref. [4,5] used finite difference to solve the fractional diffusion equation. Yang et al. [6] used the finite volume method to solve the nonlinear fractional diffusion equation. Jin et al. studied the finite element method for solving the homogeneous fractional diffusion equation in [7]. Some scholars have developed meshless methods [8,9,10,11] and spectral methods [12,13,14,15] to solve fractional diffusion equations.
The reproducing kernel space and its related theories are the ideal spatial framework for function approximation [16,17]. The function approximation in this space has uniform convergence, while the Caputo-type fractional derivative of the approximate function still has uniform convergence. Therefore, the reproducing kernel space is also the ideal spatial framework for the numerical processing of Caputo-type fractional derivatives. Numerical solutions to differential equations based on orthogonal polynomials are commonly used. For example, quartic splines and cubic splines are used, respectively, to solve numerical solutions of differential equations in Ref. [18,19,20]. In Ref. [21,22,23], based on the idea of wavelet, a multi-scale orthonormal basis is constructed in the reproducing kernel space by using piecewise polynomials, and ε-approximate solutions of integer-order differential equations are obtained.
For TFDE, most methods use the finite difference method to deal with time variables. Due to the non-singularity of fractional differentiation, the difference scheme at the initial time needs to be further transformed. And the results are not ideal; when the step size reaches 0.001, the error is only 10−5 in Ref. [10]. So, the main motivation of this paper is to obtain the ε-approximation solution of TFDE. By constructing a multiscale orthonormal basis in the multiple reproducing kernel space, a numerical algorithm is designed to obtain the approximate solution of TFDE. In order to avoid the influence of fractional non-singularity, this paper constructs the orthonormal basis by using Legendre polynomials, which can be operated by the property of fractional differentiation. In addition, the method in this paper has a good convergence order.
The paper is organized as follows: In Section 2, the fundamental definitions are provided, and Legendre polynomials and related spaces are introduced. In Section 3, the ε-approximation solutions are given. In Section 4, convergence analysis and time complexity are presented for the proposed method. In Section 5, numerical solutions for several fractional diffusion equations are presented. The paper concludes by stating the advantages of the method.
In this section, the Caputo fractional derivative and its properties are introduced. Legendre polynomials and their associated spaces are also discussed. This knowledge will be used when constructing the basis.
Definition 2.1. The Caputo fractional derivative is defined as follows [24]:
Dαtu(t)=1Γ(n−α)∫t0(t−s)n−α−1u(n)(s)ds,n=[α]+1,n−1<α<n. |
For ease of calculation, a property of the Caputo differential needs to be given here.
Property 2.1.
Dα(tγ)={Γ(γ+1)Γ(γ+1−α)tγ−α,γ≠0,0,γ=0. | (2.1) |
Proof. According to the definition of Caputo differentiation, the conclusion can be obtained using integration by parts.
Legendre polynomials are known to be orthogonal on L2[−1,1]. Since the variables being analyzed are often defined in different intervals, it is necessary to transform Legendre polynomials on [0,b]. Legendre polynomials defined on [0, b] are shown below
l0(x)=1,l1(x)=2xb−1,lj+1(x)=2j+1j+1(2xb−1)lj(x)−jj+1lj−1(x),j=1,2,⋯ |
Clearly, {lj(x)}∞j=0 is orthogonal on L2[0,b], and
∫bxli(x)lj(x)dx={b2j+1,i=j,0,i≠j. |
Let pj(x)=√2j+1blj(x), {pj(x)}∞j=0 is an orthonormal basis on L2[0,b].
Consider Eq (1.1); this section gives the following reproducing kernel space. For convenience, the absolutely continuous function is denoted as AC.
Definition 2.2. W1[0,T]={u(t)∣u(0)=0,uisAC,u′∈L2[0,T]}, and
⟨u,v⟩W1=∫T0u′v′dt,u,v∈W1[0,T]. |
If b=T and Tj(t)=pj(t), note that Tj(t)=j∑k=0cktk. Let
J0Tj(t)=∫t0Tj(τ)dτ=j∑k=0cktk+1k+1. |
Theorem 2.1. {J0Tj(t)}∞j=0 is an orthonormal basis on W1[0,T].
Definition 2.3. W2[0,b]={u(x)∣u(0)=u(b)=0,uisAC,u′′∈L2[0,b]}, and
⟨u,v⟩W2=∫b0u′′v′′dx,u,v∈W2[0,b]. |
Similarly, denote pj(x)=j∑k=0dkxk. Integrating pj(x) twice yields J20pj(x), if J20pj(x)∈W2[0,b], then
J20pj(x)=j∑k=0dkxk+2−bk+1x(k+1)(k+2). |
Obviously, {J20pj(x)}∞j=0 is an orthonormal basis on W2[0,b].
Put Ω=[0,b]×[0,T], and let's define the space W(Ω).
Definition 2.4. W(Ω)={u(x,t)∣u(x,0)=0,u(0,t)=u(b,t)=0,∂u∂x is continuous functions, ∂3u∂t∂x2∈L2(Ω)}.
Clearly, W(Ω) is an inner product space, and
⟨u,v⟩W(Ω)=∬Ω∂3u∂t∂x2∂3v∂t∂x2dσ,u,v∈W(Ω). |
Theorem 2.2. If u(x,t),v(x,t)∈W(Ω), and v(x,t)=v1(x)v2(t), then
⟨u,v⟩W(Ω)=⟨⟨u,v2⟩W1,v1⟩W2=⟨⟨u,v1⟩W2,v2⟩W1. |
Proof. Clearly,
⟨u,v⟩W(Ω)=∬Ω∂3u∂t∂x2∂3v∂t∂x2dσ=∬Ω∂∂t(∂2u∂x2)∂v2∂t∂2v1∂x2dσ=∫b0∂2∂x2(⟨u,v2⟩W1)∂2v1∂x2dx=⟨⟨u,v2⟩W1,v1⟩W2. |
Similarly, ⟨u,v⟩W(Ω)=⟨⟨u,v1⟩W2,v2⟩W1.
Note
ϕij(x,t)=J20pi(x)J0Tj(t),i,j=0,1,2,⋯. |
Theorem 2.3. {ϕij(x,t)}∞i,j=0 is an orthonormal basis on W(Ω).
Proof. First of all, orthogonality. For ∀ϕij(x,t),ϕmn(x,t)∈W(Ω), according to Theorem 2.2,
⟨ϕij(x,t),ϕmn(x,t)⟩W(Ω)=⟨J20pi(x),J20pm(x)⟩W2⟨J0Tj(t),J0Tj(t)⟩W1={1,i=m,j=n,0,others. |
Second, completeness. ∀u∈W(Ω), if ⟨u,ϕij⟩W(Ω)=0 means u≡0. In fact, by Theorem 2.4,
⟨u,ϕij⟩W(Ω)=⟨u,J20pi(x)J0Tj(t)⟩W(Ω)=⟨⟨u,J20pi(x)⟩W2,J0Tj(t)⟩W1=⟨⟨u,J0Tj(t)⟩W1,J20pi(x)⟩W2=0. |
Since {J20pi(x)}∞i=0 and {J0Tj(t)}∞j=0 are complete systems of W2[0,b] and W1[0,T], respectively, ⟨u,J20pi(x)⟩W2=0 and ⟨u,J0Tj(t)⟩W1=0. So u≡0.
Let L:W(Ω)→L2(Ω),
Lu=Dαtu−uxx. |
Then Eq (1.1) is
Lu=f. | (3.1) |
Theorem 3.1. Operator L is a bounded and linear operator.
Proof. Clearly, L is linear, and one only needs to prove boundedness. According to Cauchy Schwartz's inequality, we derive that
‖Lu‖L2≤‖Dαtu‖L2+‖uxx‖L2. |
Put K(x,t,y,s)=r(x,y)q(t,s) be the RK function in W(Ω), then
|uxx|=|⟨u(x,t),∂2K∂x2⟩W(Ω)|=|⟨u(x,t),∂2r(x,y)∂x2q(t,s)⟩W(Ω)|≤‖∂2r(x,y)∂x2q(t,s)‖W(Ω)‖u‖W(Ω). | (3.2) |
Similarly
|ut|≤‖∂q(t,s)∂tr(x,y)‖W(Ω)‖u‖W(Ω). | (3.3) |
By Eq (3.2), there exists positive constants M1 such that
‖uxx‖2L2=∬Ω(uxx)2dσ≤‖∂2r(x,y)∂x2q(t,s)‖2W(Ω)SΩ‖u‖2W(Ω)=M1‖u‖2W(Ω), | (3.4) |
where M1=‖∂2r(x,y)∂x2q(t,s)‖2W(Ω)SΩ, SΩ represents the area of the region Ω.
By Eq (3.3), there exist positive constants M2,M3, such that
|Dαtu|=|1Γ(1−α)∫t0(t−s)−αut(x,s)ds|≤1Γ(1−α)∫t0(t−s)−α|ut(x,s)|ds≤1Γ(1−α)∫t0(t−s)−α‖∂q(t,s)∂tr(x,y)‖W(Ω)‖u‖W(Ω)ds≤‖u‖W(Ω)Γ(1−α)‖∂q(t,s)∂tr(x,y)‖W(Ω)∫t0(t−s)−αds≤t1−αΓ(2−α)‖∂q(t,s)∂tr(x,y)‖W(Ω)‖u‖W(Ω)=M2‖u‖W(Ω), |
and
‖Dαtu‖2L2=∬Ω(Dαtu)2dσ≤M22SΩ‖u‖2W(Ω)=M3‖u‖2W(Ω). | (3.5) |
From Eqs (3.4) and (3.5), we can get
‖Lu‖L2≤M‖u‖W(Ω), |
where M=√M1+√M3.
Definition 3.1. uε is named the ε-approximate solution for Eq (3.1), ∀ε>0, if
‖Luε−f‖2L2<ε2. |
Ref. [21,22] proved the existence of ε−approximate solutions to boundary value problems of linear ordinary differential equations. Using the same method, we can prove that the ε-approximate solution of Eq (3.1) exists.
Theorem 3.2. ∀ε>0, ∃N1,N2>0, when n1>N1,n2>N2,
uεn1n2(x,t)=n1∑i=0n2∑j=0c∗ijϕij(x,t) |
is the ε-approximate solution of Eq (3.1), where c∗ij satisfies
‖n1∑i=0n2∑j=0c∗ijLϕij(x,t)−f(x,t)‖2L2=mincij‖n1∑i=0n2∑j=0cijLϕij(x,t)−f(x,t)‖2L2. |
Proof. Let u(x,t) be the solution of Eq (3.1),
u(x,t)=∞∑i=0∞∑j=0cijϕij(x,t), |
where cij=⟨u,ϕij⟩W(Ω), and un1n2(x,t)=∑n1i=0∑n2j=0cijϕij(x,t).
Because L is a bounded operator, ∀ε>0, ∃N1,N2>0, when n1>N1,n2>N2,
‖u−un1n2‖2W(Ω)=‖∞∑i=n1+1∞∑j=n2+1cijϕij(x,t)‖2W(Ω)≤ε‖L‖2, |
so
‖Luεn1n2−f‖2L2=‖n1∑i=0n2∑j=0c∗ijLϕij−f‖2L2=mindij‖n1∑i=0n2∑j=0dijLϕij−f‖2L2≤‖n1∑i=0n2∑j=0cijLϕij−f‖2L2≤‖Lun1n2−Lu‖2L2≤‖L‖2‖un1n2−u‖2L2≤ε. |
From Theorem 3.2, note
J(c00,c01,c02,⋯,cN1N2)=‖n1∑i=0n2∑j=0cijLϕij(x,t)−f(x,t)‖2L2, |
J is a quadratic form about c=(cij)n1,n2i,j=0, and c∗=(c∗ij)n1,n2i,j=0 is the minimum value of J. To find c∗, just need ∂J∂cij=0. That is
∂J∂cij=2n1∑i=0n2∑k=0cik⟨Lϕij,Lϕkl⟩L2−2cij⟨Lϕij,f⟩L2, |
so
n1∑i=0n2∑k=0cik⟨Lϕij,Lϕkl⟩L2=⟨Lϕij,f⟩L2. | (3.6) |
Put N=(n1+1)×(n2+1), and the N-order matrix A and the N-order vector b,
A=(⟨Lϕij,Lϕkl⟩L2)N×N,b=(⟨Lϕij,f⟩L2)N, |
so Eq (3.6) is
Ac=b. | (3.7) |
From Property 2.1,
Lϕij=Dαtϕij−∂2ϕij∂x2=J20pi(x)DαtJ0Tj(t)−pi(x)J0Tj(t)=J20pi(x)j∑k=0ckk+1Γ(k+2)tk+1−αΓ(k+2−α)−pi(x)J0Tj(t). |
From Ref. [21], if L is reversible, then Eq (3.7) exists and is unique.
Let u(x,t) be the exact solution to Eq (3.1), and
u(x,t)=∞∑i=0∞∑j=0cijϕij(x,t). |
Fourier truncation of u(x,t) is uN1,N2(x,t), and
uN1N2(x,t)=N1∑i=0N2∑j=0cijϕij(x,t). |
In Ref. [25], if u(m)(x)∈L2[0,b], then
‖u−un‖L2≤Cn−m(m∑k=min{m,n+1}‖u(k)‖2L2)12. | (4.1) |
Theorem 4.1. Assume ∂m+nu(x,t)∂tm∂xn∈L2(Ω), then
‖u(x,t)−uN1(x,t)‖W(Ω)≤C1N−m1,‖u(x,t)−uN2(x,t)‖W(Ω)≤C2N−n2, |
where C1,C2 are constants.
Proof. Recalling the definition of W(Ω), we get
‖u(x,t)−uN1(x,t)‖2W(Ω)=∬Ω∂3(u−uN1)∂t∂x2∂3(u−uN1)∂t∂x2dxdt=∫b0∫T0∂∂t(∂2(u−uN1)∂x2)∂∂t(∂2(u−uN1)∂x2)dtdx=∫b0‖∂2u∂x2−∂2uN1∂x2‖2W1dx. |
According to Eq (4.1), it follows that
‖∂2u∂x2−∂2uN1∂x2‖W1=‖∂3u∂x2∂t−∂3uN1∂x2∂t‖L2[0,T]≤C(x)N−m1(m∑k=min{m,N1+1}‖u(k+1)xx‖2L2[0,T])1/2, |
so
‖u(x,t)−uN1(x,t)‖2W(Ω)≤∫b0C2(x)N−2m1(m∑k=min{m,N−1+1}‖u(k+1)xx‖2L2[0,T])dx≤N−2m1∫b0C2(x)(m∑k=min{m,N1+1}‖u(k+1)xx‖2L2[0,T])dx≤C0N−2m1, |
where C0=∫baC2(x)(m∑k=min{m,N1+1}‖u(k+1)xx‖2L2[0,T])dx. Assume C1=√C0; that is
‖u(x,t)−uN1(x,t)‖W1≤C1N−m1. |
Similarly,
‖u(x,t)−uN2(x,t)‖W(Ω)≤C2N−n2. |
Theorem 4.2. Assume ∂m+nw(x,t)∂tm∂xn∈L2(Ω), uεN1N2(x,t) is the approximate solution of Eq (3.1), then
‖u(x,t)−uεN1N2(x,t)‖W(Ω)≤CN−γ, |
where C=2M2max{C1,C2}, N=min{N1,N2}, and γ=min{m,n}.
Proof. We know
‖u(x,t)−uεN1,N2(x,t)‖W(Ω)=‖L−1‖‖L‖‖u(x,t)−uN1,N2(x,t)‖W(Ω)≤M2‖N1∑i=0∞∑j=N1+1cijϕij(x,t)+∞∑i=N1+1∞∑j=0cijϕij(x,t)‖W(Ω)=M2(N1∑i=0∞∑j=N1+1c2ij+∞∑i=N1+1∞∑j=0c2ij), |
where M2=‖L−1‖‖L‖. Moreover,
‖u(x,t)−uN1(x,t)‖W(Ω)=‖∞∑i=0∞∑j=0cijϕij(x,t)−N1∑i=0∞∑j=0cijϕij(x,t)‖W(Ω)=‖∞∑i=N1+1∞∑j=0cijϕij(x,t)‖W(Ω)=∞∑i=N1+1∞∑j=0c2ij. |
‖u(x,t)−uN2(x,t)‖W(Ω)=‖∞∑i=0∞∑j=0cijϕij(x,t)−∞∑i=0N2∑j=0cijϕij(x,t)‖W(Ω)=‖∞∑i=0∞∑j=N2+1cijϕij(x,t)‖W(Ω)=∞∑i=0∞∑j=N2+1c2ij. |
So
‖u(x,t)−uεN1,N2(x,t)‖W(Ω)≤M2(N1∑i=0∞∑j=N1+1c2ij+∞∑i=N1+1∞∑j=0c2ij)≤M2(∞∑i=0∞∑j=N1+1c2ij+∞∑i=N1+1∞∑j=0c2ij)=M2(‖u(x,t)−uN2(x,t)‖W(Ω)+‖u(x,t)−uN1(x,t)‖W(Ω))≤M2(C1N−m1+C2N−n2)≤CNγ. |
So, the proposed method is γ-order convergence, and the convergence rate depends on N.
The proposal of an algorithm requires not only a reliable theory but also the feasibility of calculation. The huge calculation process is costly. Next, the time complexity of the algorithm will be analyzed.
According to the analysis in Section 3, the complexity of the algorithm depends on Eqs (3.6) and (3.7). Next, the algorithm can be illustrated in four steps, as follows:
(1) A of Eq (3.7). We know A=(⟨Lϕij,Lϕkl⟩L2)N×N, and
⟨Lϕij,Lϕkl⟩L2=∫10J20pi(x)J20pk(x)dx∫10J0Tj(t)J0Tl(t)dt. |
Set the number of multiplications required to compute ⟨Lϕij,Lϕkl⟩L2 as C1, where C1 is constant. Clearly, the computing time needed for A is Num1=C1N2.
(2) b of Eq (3.7). We know b=(⟨Lϕij,f⟩L2)N×N, and
⟨Lϕij,f⟩L2=∫10∫10J20pi(x)J0Tj(t)dtdx. |
Set the number of multiplications required to compute ⟨Lϕij,f⟩L2 as C2, where C1 is constant. Clearly, the computing time needed for b is Num2=C2N.
(3) We use the Gaussian elimination method to solve Eq (3.7). From my mathematical knowledge, Gaussian elimination requires operations
Num3=N(N+1)(2N+1))6. |
(4) To the ε−approximation solution uεN(x,t), the number of computations is N.
In summary, the multiplication times of this algorithm in the execution process are
Num=Num1+Num2+Num3+N=O(N3). |
This section discusses three numerical examples to reveal the accuracy of the proposed algorithm. Compared with Ref. [26,27,28,29], the results demonstrate that our method is remarkably effective. All the results are calculated using the mathematical software Mathematica 13.0.
In this paper, N=N1×N2 is the number of bases, and eN(x)=|u(x)−uN(x)| is the absolute error. MEN denotes the maximum absolute error when the number of bases is N. The convergence order can be calculated as follows:
C.R.=LogNMmax|eM|max|eN|. |
Example 5.1. Consider the test problem suggested in [26,27]
{Dαtu(x,t)=uxx(x,t)+f(x,t),(x,t)∈(0,1)×(0,1],u(x,0)=0,x∈(0,1),u(0,t)=0,u(1,t)=0, |
where f(x)=3√π4Γ(2.5−α)x4(x−1)t1.5−α−(20x3−12x2)t1.5, and the analytical solution is given by u(x,t)=x4(x−1)t1.5. The numerical results are shown in Tables 1 and 2. Table 1 shows that when α is 0.5 or 0.8, respectively, our results are better than those in Ref. [26,27]. Meanwhile, we also show the results when α=0.01 and α=0.99 in Table 1 and find that the results are not much different from those when a = 0.5 and a = 0.8, demonstrating the robustness of our method. Table 2 indicates that the absolute error gets better as the number of bases increases. Figures 1 and 2 shows the absolute errors when α=0.01 and α=0.99, respectively. Figures 3 and 4 show the absolute errors at different times when α=0.01 and α=0.99.
α(t) | MEN in [26] | MEN in [27] | ME36 | ME64 |
0.5 | 8.82×10−4 | 1.99×10−4 | 1.41×10−5 | 4.18×10−6 |
0.8 | 8.50×10−4 | 1.87×10−4 | 7.16×10−6 | 4.61×10−6 |
0.01 | 1.43×10−5 | 4.09×10−6 | ||
0.99 | 2.95×10−5 | 6.03×10−6 |
n | α=0.5 | C.R. | α=0.8 | C.R. |
9 | 8.08×10−3 | 7.75×10−3 | ||
16 | 6.07×10−4 | 4.50 | 6.12×10−5 | 8.41 |
25 | 2.75×10−5 | 6.93 | 2.76×10−5 | 1.78 |
36 | 1.41×10−5 | 1.83 | 1.41×10−5 | 1.84 |
49 | 8.10×10−6 | 1.80 | 8.04×10−6 | 1.82 |
64 | 4.18×10−6 | 2.48 | 4.61×10−6 | 2.08 |
Example 5.2. We consider the same FDEs as that in [28]
{Dαtu(x,t)=uxx(x,t)+f(x,t),(x,t)∈(0,1)×(0,1],u(x,0)=0,x∈(0,1),u(0,t)=0,u(1,t)=0. |
With f(x,t)=2Γ(3−α)t2−αsin(2πx)+4π2t2sin(2πx), the exact solution of the problem is given by u(x,t)=t2sin(2πx). Tables 3–5, respectively, show the comparison of absolute error and convergence order with Ref. [28] when α is 0.2, 0.5, or 0.8. Obviously, the proposed method is superior to Ref. [28]. N×L denotes the number of bases in Ref.[28].
[28] | Our method | |||||
N×L | ME | C.R. | N1×N2 | MEN | C.R. | |
25×L | 2.06×10−6 | 4.00 | 4×8 | 1.95×10−5 | ||
30×L | 1.00×10−6 | 4.00 | 4×10 | 3.11×10−7 | 18.54 | |
35×L | 5.39×10−7 | 4.00 | 4×12 | 2.72×10−9 | 25.99 | |
40×L | 3.15×10−7 | 4.01 | 4×14 | 3.21×10−11 | 28.79 |
[28] | Our method | |||||
N×L | ME | C.R. | N1×N2 | MEN | C.R. | |
25×L | 2.65×10−6 | 4.01 | 4×8 | 1.95×10−5 | ||
30×L | 9.96×10−7 | 4.03 | 4×10 | 3.10×10−7 | 18.56 | |
35×L | 5.35×10−7 | 4.06 | 4×12 | 3.72×10−9 | 24.25 | |
40×L | 3.11×10−7 | 4.11 | 4×14 | 1.29×10−10 | 36.74 |
[28] | Our method | |||||
N×L | ME | C.R. | N1×N2 | MEN | C.R. | |
25×L | 2.03×10−6 | 4.13 | 4×8 | 1.93×10−5 | ||
30×L | 9.65×10−7 | 4.30 | 4×10 | 3.08×10−7 | 18.54 | |
35×L | 5.04×10−7 | 4.61 | 4×12 | 3.08×10−9 | 24.69 | |
40×L | 2.85×10−7 | 5.18 | 4×14 | 4.80×10−10 | 13.11 |
Example 5.3. Considering the following problem with f(x,t)=Γ(4+α)6sin(πx)+π2t3+αsin(πx)+πt3+αcos(πx) [29]:
{Dαtu(x,t)=uxx(x,t)−ux+f(x,t),(x,t)∈(0,1)×(0,1],u(x,0)=0,x∈(0,1),u(0,t)=0,u(1,t)=0. |
The exact solution of the problem is given by u(x,t)=t3+αsin(πx). Table 6 shows the comparison of absolute error and convergence order with Ref. [29] when α is 0.1. Obviously, the proposed method is superior to Ref. [29]. Figures 5–7 show the absolute errors when α=0.1, α=0.01 and α=0.99 respectively.
[29] | Our method | |||||
N×L | ME | C.R. | N1×N2 | MEN | C.R. | |
20×20 | 1.44×10−3 | – | 3×3 | 1.40×10−3 | – | |
40×40 | 3.66×10−4 | 1.98 | 5×5 | 1.83×10−5 | 4.01 | |
80×80 | 9.15×10−5 | 1.98 | 7×7 | 2.89×10−6 | 3.09 | |
160×160 | 2.31×10−5 | 1.98 | 9×9 | 2.83×10−7 | 4.62 |
In this paper, an effective numerical algorithm based on Legendre polynomials is proposed for TFDE. Based on Legendre polynomials, an orthonormal basis is constructed in the reproducing kernel spaces W1[0,1] and W2[0,b]. Then we define the multiple reproducing kernel space and develop the orthonormal basis in this space. The ε-approximate solution of TFDE is obtained. From the above analysis and the numerical examples, it is clear that the presented method is successfully employed for solving TFDE. The numerical results show that our method is much more accurate than other algorithms. In this paper, because the orthonormal basis constructed in the binary reproducing kernel space contains power terms, the properties of fractional differentiation can be used to calculate fractional differentiation, so as to eliminate the influence of the non-singularity of fractional differentiation. However, the method presented in this paper is suitable for the case where the initial boundary value condition is 0, and for the non-zero case, it needs to be further simplified to the cases where the initial boundary value condition is 0. We are also trying to design methods for cases where initial boundary values are non-zero.
Yingchao Zhang: Conceived of the study, designed the study, and proved the convergence of the algorithm; Yingzhen Lin: Reviewed the full text. All authors were involved in writing the manuscript. All authors read and approved the final manuscript.
The authors declare they have not used Artificial Intelligence (AI) tools in the creation of this article.
This study was supported by the Characteristic Innovative Scientific Research Project of Guangdong Province (2023KTSCX181, 2023KTSCX183) and Basic and Applied Basic Research Project Zhuhai City (2320004002520)
The authors have no conflicts of interest to declare.
[1] | CDCHeart Disease Facts, 2020. Available from: https://www.cdc.gov/heartdisease/facts.htm |
[2] | FDATable of Pharmacogenomic Biomarkers in Drug Labeling. Science and Research | Drugs, 2021. Available from: https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling |
[3] |
Ford NF (2016) The Metabolism of Clopidogrel: CYP2C19 Is a Minor Pathway. J Clin Pharmacol 56: 1474-1483. https://doi.org/10.1002/jcph.769 ![]() |
[4] | Beavers CJ, Naqvi IA (2021) Clopidogrel, in StatPearls. StatPearls Publishing: Treasure Island, FL. |
[5] | Pharm VarCYP2C19, 2021. Available from: https://www.pharmvar.org/gene/CYP2C19 |
[6] | Pharm GKBCYP2C19, 2021. Available from: https://www.pharmgkb.org/gene/PA124#tabviewZtab4&subtabZ31 |
[7] |
Scott SA, Sangkuhl K, Gardner EE, et al. (2013) Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 94: 317-323. https://doi.org/10.1038/clpt.2013.105 ![]() |
[8] | Sangkuhl K Very Important Pharmacogene: CYP2C19, 2018. Available from: https://www.pharmgkb.org/vip/PA166169770 |
[9] | FDAFDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug, 2010. Available from: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-reduced-effectiveness-plavix-clopidogrel-patients-who-are-poor |
[10] |
Lyu SQ, Yang YM, Zhu J, et al. (2020) The efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy compared with conventional antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. Platelets 31: 971-980. https://doi.org/10.1080/09537104.2020.1780205 ![]() |
[11] |
Zheng L, Yang C, Xiang L, et al. (2019) Genotype-guided antiplatelet therapy compared with conventional therapy for patients with acute coronary syndromes: a systematic review and meta-analysis. Biomarkers 24: 517-523. https://doi.org/10.1080/1354750X.2019.1634764 ![]() |
[12] |
Daniel M.F. Claassens, Gerrit J.A. Vos, Thomas O. Bergmeijer, et al. (2019) A Genotype-Guided Strategy for Oral P2Y. N Engl J Med 381: 1621-1631. https://doi.org/10.1056/NEJMoa1907096 ![]() |
[13] |
Pereira NL, Farkouh ME, So D, et al. (2020) Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. JAMA 324: 761-771. https://doi.org/10.1001/jama.2020.12443 ![]() |
[14] |
Kheiri B, Osman M, Abdalla A, et al. (2019) CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials. Catheter Cardiovasc Interv 93: 1246-1252. https://doi.org/10.1002/ccd.27949 ![]() |
[15] |
Boccardo P, Remuzzi G, Galbusera M (2004) Platelet dysfunction in renal failure. Semin Thromb Hemost 30: 579-589. https://doi.org/10.1055/s-2004-835678 ![]() |
[16] |
Pratt VM, Tredici ALD, Hachad H, et al. (2018) Recommendations for Clinical CYP2C19 Genotyping Allele Selection: A Report of the Association for Molecular Pathology. J Mol Diagn 20: 269-276. https://doi.org/10.1016/j.jmoldx.2018.01.011 ![]() |
[17] | Tantry US, Hennekens CH, Zehnder JL, et al. Clopidogrel resistance and clopidogrel treatment failure. Waltham, MA: UpToDate, Waltham, MA. |
[18] |
Bonello L, Tantry U, Marcucci R, et al. (2021) Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56: 919-933. https://doi.org/10.1016/j.jacc.2010.04.047 ![]() |
[19] |
Levine G, Bates E, Bittl J, et al. (2016) 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Thorac Cardiovasc Surg 152: 1243-1275. https://doi.org/10.1016/j.jacc.2016.03.513 ![]() |
[20] | Pratt VM, Scott SA, Pirmohamed M, et al. (2012) Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US) 2012. |
[21] |
Adamski P., Buszko K., Sikora J., et al. (2018) Metabolism of ticagrelor in patients with acute coronary syndromes. Sci Rep 8: 11746. https://doi.org/10.1038/s41598-018-29619-9 ![]() |
[22] |
Mohitosh Biswas, Most Sumaiya Khatun Kali, Tapash Kumar Biswas, et al. (2021) Risk of major adverse cardiovascular events of CYP2C19 loss-of-function genotype guided prasugrel/ticagrelor vs clopidogrel therapy for acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis. Platelets 32: 591-600. https://doi.org/10.1080/09537104.2020.1792871 ![]() |
[23] |
Stefan James, Dominick J. Angiolillo, Jan H. Cornel, et al. (2010) Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 31: 3006-3016. https://doi.org/10.1093/eurheartj/ehq325 ![]() |
[24] |
Turgeon RD, Koshman SL, Youngson E, et al. (2020) Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. JAMA Intern Med 180: 420-428. https://doi.org/10.1001/jamainternmed.2019.6447 ![]() |
[25] |
Wallentin L, Becker RC, Budaj A, et al. (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361: 1045-1057. https://doi.org/10.1056/NEJMoa0904327 ![]() |
[26] |
Anders Sahlén, Christoph Varenhorst, Bo Lagerqvist, et al. (2016) Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry. Eur Heart J 37: 3335-3342. https://doi.org/10.1093/eurheartj/ehw284 ![]() |
[27] |
Wiviott SD, Braunwald E, McCabe CH, et al. (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357: 2001-2015. https://doi.org/10.1056/NEJMoa0706482 ![]() |
[28] | (1968) WHONutritional anaemias: Report of a WHO scientific group. Geneva, Switzerland: World Health Organization. |
[29] |
Urban P, Mehran R, Colleran R, et al. (2019) Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J 40: 2632-2653. https://doi.org/10.1093/eurheartj/ehz372 ![]() |
[30] |
Scott SA, Sangkuhl K, Gardner EE, et al. (2011) Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 90: 328-332. https://doi.org/10.1038/clpt.2011.132 ![]() |
[31] |
Lee CC, McMillin GA, Babi N, et al. (2011) Evaluation of a CYP2C19 genotype panel on the GenMark eSensor® platform and the comparison to the Autogenomics Infiniti™ and Luminex CYP2C19 panels. Clin Chim Acta 412: 1133-1137. https://doi.org/10.1016/j.cca.2011.03.001 ![]() |
[32] |
Ferreira IA, Eybrechts KL, Mocking AIM, et al. (2004) IRS-1 mediates inhibition of Ca2+ mobilization by insulin via the inhibitory G-protein Gi. J Biol Chem 279: 3254-3264. https://doi.org/10.1074/jbc.M305474200 ![]() |
[33] |
Ferreira IA, Mocking AIM, Feijge MAH, et al. (2006) Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 26: 417-422. https://doi.org/10.1161/01.ATV.0000199519.37089.a0 ![]() |
[34] |
Chouchene S., Dabboubi R., Raddaoui H., et al. (2018) Clopidogrel utilization in patients with coronary artery disease and diabetes mellitus: should we determine CYP2C19*2 genotype?. Eur J Clin Pharmacol 74: 1567-1574. https://doi.org/10.1007/s00228-018-2530-5 ![]() |
[35] |
Ang L, Palakodeti V, Khalid A, et al. (2008) Elevated Plasma Fibrinogen and Diabetes Mellitus Are Associated With Lower Inhibition of Platelet Reactivity With Clopidogrel. J Am Coll Cardiol 52: 1052-1059. https://doi.org/10.1016/j.jacc.2008.05.054 ![]() |
[36] |
Nardin M, Verdoia M, Sartori C, et al. (2015) Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor. J Cardiovasc Pharmacol 66: 364-370. https://doi.org/10.1097/FJC.0000000000000288 ![]() |
[37] |
Shang LL, Guo DD, Zhao HY, et al. (2018) Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease. J Clin Pharm Ther 43: 342-347. https://doi.org/10.1111/jcpt.12651 ![]() |
[38] |
Ferlini M, Musumeci G, Grieco N, et al. (2018) The paradox of clopidogrel use in patients with acute coronary syndromes and diabetes: insight from the Diabetes and Acute Coronary Syndrome Registry. Coron Artery Dis 29: 309-315. https://doi.10.1097/MCA.0000000000000601 ![]() |
[39] |
Mohareb MW, AbdElghany M, Zaki HF, et al. Diabetes and CYP2C19 Polymorphism Synergistically Impair the Antiplatelet Activity of Clopidogrel Compared With Ticagrelor in Percutaneous Coronary Intervention-treated Acute Coronary Syndrome Patients. J Cardiovasc Pharmacol 76: 478-488. https://doi.org/10.1097/FJC.0000000000000881 ![]() |
[40] |
Mo J, Chen Z, Xu J, et al. (2019) Efficacy of Clopidogrel-Aspirin Therapy for Stroke Does Not Exist in. Stroke 51: 224-231. https://doi.org/10.1161/STROKEAHA.119.026845 ![]() |
[41] |
Zeb I, Krim N, Jonathan B (2018) Role of CYP2C19 genotype testing in clinical use of clopidogrel: is it really useful?. Expert Review of Cardiovascular Therapy 16: 369-377. https://doi.org/10.1080/14779072.2018.1459186 ![]() |
[42] | Services, U.S.C.f.M.MCSV. Open Data, 2021. Available from: https://data.medicaid.gov/dataset/d5eaf378-dcef-5779-83de-acdd8347d68e/data?conditions[0][property]=as_of_date&conditions[0][value]=10%2F20%2F2021&conditions[0][operator]=%3D |
[43] |
Li J, Qiu H, Yan L, et al. (2021) Efficacy and Safety of Ticagrelor and Clopidogrel in Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. J Atheroscler Thromb 28: 873-882. https://doi.org/doi.10.5551/jat.57265 ![]() |
[44] |
Dong OM, Wheeler SB, Cruden G, et al. (2020) Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention. Value Health 23: 61-73. https://doi.org/10.1016/j.jval.2019.08.002 ![]() |
[45] |
Einarson TR, Acs A, Ludwig C, et al. (2018) Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovascular Diabetology 17: 1-19. https://doi.org/10.1186/s12933-018-0728-6 ![]() |
[46] | WHOObesity and overweight Factsheets, 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight |
1. | Liangying Miao, Man Xu, Zhiqian He, Existence and multiplicity of positive solutions for one-dimensional $ p $-Laplacian problem with sign-changing weight, 2023, 31, 2688-1594, 3086, 10.3934/era.2023156 |
n | α=0.5 | C.R. | α=0.8 | C.R. |
9 | 8.08×10−3 | 7.75×10−3 | ||
16 | 6.07×10−4 | 4.50 | 6.12×10−5 | 8.41 |
25 | 2.75×10−5 | 6.93 | 2.76×10−5 | 1.78 |
36 | 1.41×10−5 | 1.83 | 1.41×10−5 | 1.84 |
49 | 8.10×10−6 | 1.80 | 8.04×10−6 | 1.82 |
64 | 4.18×10−6 | 2.48 | 4.61×10−6 | 2.08 |
[28] | Our method | |||||
N×L | ME | C.R. | N1×N2 | MEN | C.R. | |
25×L | 2.06×10−6 | 4.00 | 4×8 | 1.95×10−5 | ||
30×L | 1.00×10−6 | 4.00 | 4×10 | 3.11×10−7 | 18.54 | |
35×L | 5.39×10−7 | 4.00 | 4×12 | 2.72×10−9 | 25.99 | |
40×L | 3.15×10−7 | 4.01 | 4×14 | 3.21×10−11 | 28.79 |
[28] | Our method | |||||
N×L | ME | C.R. | N1×N2 | MEN | C.R. | |
25×L | 2.65×10−6 | 4.01 | 4×8 | 1.95×10−5 | ||
30×L | 9.96×10−7 | 4.03 | 4×10 | 3.10×10−7 | 18.56 | |
35×L | 5.35×10−7 | 4.06 | 4×12 | 3.72×10−9 | 24.25 | |
40×L | 3.11×10−7 | 4.11 | 4×14 | 1.29×10−10 | 36.74 |
[28] | Our method | |||||
N×L | ME | C.R. | N1×N2 | MEN | C.R. | |
25×L | 2.03×10−6 | 4.13 | 4×8 | 1.93×10−5 | ||
30×L | 9.65×10−7 | 4.30 | 4×10 | 3.08×10−7 | 18.54 | |
35×L | 5.04×10−7 | 4.61 | 4×12 | 3.08×10−9 | 24.69 | |
40×L | 2.85×10−7 | 5.18 | 4×14 | 4.80×10−10 | 13.11 |
[29] | Our method | |||||
N×L | ME | C.R. | N1×N2 | MEN | C.R. | |
20×20 | 1.44×10−3 | – | 3×3 | 1.40×10−3 | – | |
40×40 | 3.66×10−4 | 1.98 | 5×5 | 1.83×10−5 | 4.01 | |
80×80 | 9.15×10−5 | 1.98 | 7×7 | 2.89×10−6 | 3.09 | |
160×160 | 2.31×10−5 | 1.98 | 9×9 | 2.83×10−7 | 4.62 |
α(t) | MEN in [26] | MEN in [27] | ME36 | ME64 |
0.5 | 8.82×10−4 | 1.99×10−4 | 1.41×10−5 | 4.18×10−6 |
0.8 | 8.50×10−4 | 1.87×10−4 | 7.16×10−6 | 4.61×10−6 |
0.01 | 1.43×10−5 | 4.09×10−6 | ||
0.99 | 2.95×10−5 | 6.03×10−6 |
n | α=0.5 | C.R. | α=0.8 | C.R. |
9 | 8.08×10−3 | 7.75×10−3 | ||
16 | 6.07×10−4 | 4.50 | 6.12×10−5 | 8.41 |
25 | 2.75×10−5 | 6.93 | 2.76×10−5 | 1.78 |
36 | 1.41×10−5 | 1.83 | 1.41×10−5 | 1.84 |
49 | 8.10×10−6 | 1.80 | 8.04×10−6 | 1.82 |
64 | 4.18×10−6 | 2.48 | 4.61×10−6 | 2.08 |
[28] | Our method | |||||
N×L | ME | C.R. | N1×N2 | MEN | C.R. | |
25×L | 2.06×10−6 | 4.00 | 4×8 | 1.95×10−5 | ||
30×L | 1.00×10−6 | 4.00 | 4×10 | 3.11×10−7 | 18.54 | |
35×L | 5.39×10−7 | 4.00 | 4×12 | 2.72×10−9 | 25.99 | |
40×L | 3.15×10−7 | 4.01 | 4×14 | 3.21×10−11 | 28.79 |
[28] | Our method | |||||
N×L | ME | C.R. | N1×N2 | MEN | C.R. | |
25×L | 2.65×10−6 | 4.01 | 4×8 | 1.95×10−5 | ||
30×L | 9.96×10−7 | 4.03 | 4×10 | 3.10×10−7 | 18.56 | |
35×L | 5.35×10−7 | 4.06 | 4×12 | 3.72×10−9 | 24.25 | |
40×L | 3.11×10−7 | 4.11 | 4×14 | 1.29×10−10 | 36.74 |
[28] | Our method | |||||
N×L | ME | C.R. | N1×N2 | MEN | C.R. | |
25×L | 2.03×10−6 | 4.13 | 4×8 | 1.93×10−5 | ||
30×L | 9.65×10−7 | 4.30 | 4×10 | 3.08×10−7 | 18.54 | |
35×L | 5.04×10−7 | 4.61 | 4×12 | 3.08×10−9 | 24.69 | |
40×L | 2.85×10−7 | 5.18 | 4×14 | 4.80×10−10 | 13.11 |
[29] | Our method | |||||
N×L | ME | C.R. | N1×N2 | MEN | C.R. | |
20×20 | 1.44×10−3 | – | 3×3 | 1.40×10−3 | – | |
40×40 | 3.66×10−4 | 1.98 | 5×5 | 1.83×10−5 | 4.01 | |
80×80 | 9.15×10−5 | 1.98 | 7×7 | 2.89×10−6 | 3.09 | |
160×160 | 2.31×10−5 | 1.98 | 9×9 | 2.83×10−7 | 4.62 |